NCT01958827View on ClinicalTrials.gov

A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

October 31, 2015

Conditions
Crohn's Disease
Interventions
BIOLOGICAL

Adalimumab

Adalimumab pre-filled syringe, administered by subcutaneous injection.

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY